uniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130
Source: SeekingAlpha
2026-03-02 16:59:18 ET
More on uniQure
- uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
- uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
- uniQure: Now What?
- UniQure outlines next steps for Huntington’s program as FDA recommends Phase III sham-controlled trial
- uniQure falls after FDA commissioner’s comments on rare disease therapy
Read the full article on Seeking Alpha
For further details see:
uniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130
uniQure N.V.
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
QURE Latest News
April 30, 2026 07:05:00 am
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
QURE Stock Data
$1,555,111,367
59,307,892
N/A
61
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
